AstraZeneca's $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win – Fierce Biotech

Written by

admin

in

  1. AstraZeneca’s $1.3B bet reduces blood pressure by 14 mmHg over 12 weeks in phase 3 win  Fierce Biotech
  2. Astrazeneca Says Hypertension Drug Meets Main, Secondary Goals in Phase 3 Study  MarketScreener
  3. Baxdrostat demonstrated a statistically…

Continue Reading

More posts